Submitted by Anonymous (not verified) on 22 November 2023 - 11:53
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Angioedemas, Hereditary, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised
Source: